A J van der Lely Selected Research

pegvisomant

4/2017	A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.
5/2016	What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
5/2016	Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
11/2015	Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
8/2015	Pregnancy in acromegaly patients treated with pegvisomant.
3/2015	Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
10/2014	Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly.
5/2012	Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
9/2011	Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
6/2011	Combination treatment with somatostatin analogues and pegvisomant in acromegaly.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A J van der Lely Research Topics

Disease

30	Acromegaly 03/2021 - 04/2000
14	Neoplasms (Cancer) 01/2020 - 04/2004
10	Pituitary Neoplasms (Pituitary Adenoma) 01/2020 - 07/2004
8	Pituitary ACTH Hypersecretion 08/2016 - 10/2006
7	Obesity 01/2017 - 11/2003
7	Insulin Resistance 10/2013 - 11/2001
5	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2013 - 01/2005
4	Cushing Syndrome 04/2014 - 10/2006
3	Prader-Willi Syndrome (Syndrome, Prader-Willi) 01/2016 - 12/2015
3	ACTH-Secreting Pituitary Adenoma 11/2011 - 01/2005
2	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2019 - 06/2018
2	Weight Loss (Weight Reduction) 01/2017 - 01/2006
2	Type 2 Diabetes Mellitus (MODY) 01/2016 - 11/2011
2	Breast Neoplasms (Breast Cancer) 01/2016 - 01/2001
2	Fatigue 01/2016 - 04/2000
2	Hyperglycemia 03/2014 - 10/2001
2	Carcinoid Tumor (Carcinoid) 02/2009 - 12/2003
2	Prolactinoma (Prolactinomas) 01/2005 - 01/2005
2	Anorexia Nervosa 10/2004 - 04/2004
2	Diabetes Mellitus 07/2004 - 01/2001
2	Cachexia 04/2004 - 12/2003
1	Familial Isolated Pituitary Adenoma 01/2020
1	Follicular Adenocarcinoma 01/2020
1	Craniopharyngioma (Craniopharyngiomas) 01/2017
1	Hypopituitarism (Sheehan's Syndrome) 01/2017
1	Osteoporosis 08/2016
1	Metabolic Bone Diseases (Osteopenia) 08/2016
1	Thyroid Neoplasms (Thyroid Cancer) 01/2016
1	Thyroid Nodule (Nodule, Thyroid) 01/2016
1	Overweight 01/2016
1	Hyperphagia (Overeating) 12/2015
1	Body Weight (Weight, Body) 11/2015
1	Adenoma (Adenomas) 01/2014
1	Pain (Aches) 12/2013
1	Flushing 10/2013
1	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/2013
1	Lipodystrophy 05/2012
1	Gigantism 09/2011
1	Metabolic Diseases (Metabolic Disease) 01/2011
1	Growth Disorders 01/2011
1	Carcinoma (Carcinomatosis) 01/2009
1	Small Cell Carcinoma 01/2009
1	Sepsis (Septicemia) 01/2009
1	Adrenocortical Carcinoma 07/2007
1	Hyperplasia 10/2006
1	Chemical and Drug Induced Liver Injury 06/2006
1	Drug-Related Side Effects and Adverse Reactions 06/2006
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2006
1	Necrosis 01/2006
1	Inflammation (Inflammations) 01/2006

Drug/Important Bio-Agent (IBA)

18	pegvisomant FDA LinkGeneric 04/2017 - 04/2000
17	GhrelinIBA 01/2019 - 10/2001
16	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 05/2016 - 08/2000
12	Insulin-Like Growth Factor I (IGF-1)IBA 05/2016 - 04/2000
9	Growth Hormone (Somatotropin)IBA 08/2016 - 04/2000
7	Adrenocorticotropic Hormone (ACTH)FDA Link 08/2014 - 11/2003
5	Insulin (Novolin)FDA Link 05/2016 - 11/2001
5	Somatostatin Receptors (Somatostatin Receptor)IBA 11/2015 - 01/2005
4	Somatotropin Receptors (Growth Hormone Receptor)IBA 04/2017 - 04/2000
4	Glucose (Dextrose)FDA LinkGeneric 03/2014 - 11/2003
4	Octreotide (Sandostatin)FDA LinkGeneric 03/2014 - 12/2003
4	Hormones (Hormone)IBA 02/2013 - 01/2005
3	Insulin-Like PeptidesIBA 11/2015 - 06/2011
3	EnzymesIBA 03/2015 - 06/2006
3	Hydrocortisone (Cortisol)FDA LinkGeneric 04/2014 - 10/2006
3	pasireotideIBA 03/2014 - 02/2009
2	LigandsIBA 11/2015 - 02/2013
2	Peptides (Polypeptides)IBA 08/2014 - 01/2005
2	des-n-octanoyl ghrelinIBA 10/2013 - 11/2011
1	DNA (Deoxyribonucleic Acid)IBA 01/2020
1	RacivirIBA 01/2020
1	aryl hydrocarbon receptor-interacting proteinIBA 01/2020
1	Metformin (Glucophage)FDA LinkGeneric 06/2018
1	insulin receptor-related receptor (IRR)IBA 03/2015
1	Dexamethasone (Maxidex)FDA LinkGeneric 04/2014
1	SteroidsIBA 12/2013
1	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2013
1	Insulin-Like Growth Factor Binding Protein 1IBA 04/2012
1	Corticotropin Receptors (ACTH Receptor)IBA 11/2011
1	AdipokinesIBA 06/2011
1	AdiponectinIBA 06/2011
1	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)IBA 02/2009
1	Protein Isoforms (Isoforms)IBA 07/2007
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2006
1	Interleukin-6 (Interleukin 6)IBA 01/2006
1	CytokinesIBA 01/2006
1	LeptinIBA 01/2006
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2006
1	PPAR-gamma AgonistsIBA 01/2006
1	somatotropin-binding protein (growth hormone-binding protein)IBA 12/2005
1	AcidsIBA 12/2005

Therapy/Procedure

20	Therapeutics 03/2021 - 08/2000
8	Radiotherapy 08/2016 - 04/2000
2	Adrenalectomy 01/2009 - 10/2006
2	Drug Therapy (Chemotherapy) 01/2004 - 08/2000
1	Gastrectomy 01/2017
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2017
1	Hormone Replacement Therapy (Therapy, Hormone Replacement) 01/2017
1	Bariatric Surgery 01/2017
1	Estrogen Replacement Therapy 01/2016